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Abstract
Background: The cross-talk between pathogenic T lymphocytes and regulatory T cells (Tregs) plays a major role in the
progression of autoimmune diseases. Our objective is to identify molecules and/or pathways involved in this interaction and
representing potential targets for innovative therapies. Glucocorticoid-induced tumor necrosis factor receptor (GITR) and its
ligand are key players in the T effector/Treg interaction. GITR is expressed at low levels on resting T cells and is significantly
up-regulated upon activation. Constitutive high expression of GITR is detected only on Tregs. GITR interacts with its ligand
mainly expressed on antigen presenting cells and endothelial cells. It has been suggested that GITR triggering activates
effector T lymphocytes while inhibiting Tregs thus contributing to the amplification of immune responses. In this study, we
examined the role of GITR/GITRLigand interaction in the progression of autoimmune diabetes.
Methods and Findings: Treatment of 10-day-old non-obese diabetic (NOD) mice, which spontaneously develop diabetes,
with an agonistic GITR-specific antibody induced a significant acceleration of disease onset (80% at 12 weeks of age). This
activity was not due to a decline in the numbers or functional capacity of CD4
+CD25
+Foxp3
+ Tregs but rather to a major
activation of ‘diabetogenic’ T cells. This conclusion was supported by results showing that anti-GITR antibody exacerbates
diabetes also in CD28
2/2 NOD mice, which lack Tregs. In addition, treatment of NOD mice, infused with the diabetogenic
CD4
+BDC2.5 T cell clone, with GITR-specific antibody substantially increased their migration, proliferation and activation
within the pancreatic islets and draining lymph nodes. As a mirror image, blockade of the GITR/GITRLigand pathway using a
neutralizing GITRLigand-specific antibody significantly protected from diabetes even at late stages of disease progression.
Experiments using the BDC2.5 T cell transfer model suggested that the GITRLigand antibody acted by limiting the homing
and proliferation of pathogenic T cells in pancreatic lymph nodes.
Conclusion: GITR triggering plays an important costimulatory role on diabetogenic T cells contributing to the development
of autoimmune responses. Therefore, blockade of the GITR/GITRLigand pathway appears as a novel promising clinically
oriented strategy as GITRLigand-specific antibody applied at an advanced stage of disease progression can prevent overt
diabetes.
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Introduction
The glucocorticoid-induced tumor necrosis factor receptor
(GITR, also known as TNFRSF18) belongs to the TNF-nerve
growth factor receptor gene superfamily and is expressed by a
variety of immune cells. Resting CD4
+ and CD8
+ T cells, NK
cells, B cells, macrophages and dendritic cells (DCs) express low
levels of GITR [1]. At the T cell surface, GITR expression
increases following activation. Attention was initially drawn to
GITR as a new marker for CD4
+CD25
+ regulatory T cells (Tregs),
essential for the control of a variety of immune responses
(autoantigens, infectious and tumor antigens, allergens and
alloantigens) [2,3] which constitutively express high levels of the
molecule [1,4]. Several reports suggest that signaling through
GITR abrogates the suppressive functions of Tregs. In vitro,
addition of mouse-specific anti-GITR antibodies reverses the in
vitro suppressive capacity of Tregs [1,4]. It has been demonstrated
that GITR acts as a costimulatory molecule [5,6]. Thus, GITR
triggering enhances T cell proliferation and cytokine production in
response to T cell receptor (TCR) stimulation. Moreover, GITR
cross-linking inhibits T cell receptor-induced apoptosis [7–9] and
sustains T cell survival and responsiveness by triggering three
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NF-kB [6,10,11].
In the mouse, the ligand of GITR (GITRL) is expressed on
endothelial cells and antigen presenting cells (APCs) including
dendritic cells (DCs), macrophages and B cells [5,6,12]. Its
expression is up-modulated by various pro-inflammatory stimuli
[5,6]. At variance, in the human a more restricted distribution was
described. Besides endothelial cells, human GITRL is exclusively
detected on activated plasmacytoid DCs (but not on T cells, B
cells, NK cells, macrophages, mature or immature myeloid DCs)
[13,14]. In addition, over expression of GITRL in human
monocyte-derived DCs enhances their capacity to activate T cells
by providing costimulatory signals [14]. In macrophages, GITRL
signaling leads to the production of pro-inflammatory mediators
such as IL-1b, IL-8, TNF-a, MCP-1, inducible nitric oxide
synthetase (iNOS) and matrix metalloproteinase (MMP)-9 [15,16].
Interestingly, a recent report showed that, in mouse, plasmacytoid
DCs reverse signaling through GITRL could also activate
indoleamine 2,3-dioxygenase (IDO) thus inducing a major
down-regulatory loop though the tryptophan catabolism regula-
tory pathway [17].
Compelling evidence has accumulated to show that in vivo
triggering of GITR with an agonistic monoclonal antibody
significantly up-regulates immune responses to tumors and
infectious agents thus facilitating their eradication, and so
representing a suitable ‘adjuvant’ strategy in these situations
[18–22]. In keeping with these observations are data showing that
treatment with anti-GITR also exacerbates the development of
autoimmune and allergic disorders including autoimmune gastritis
[1], experimental autoimmune encephalomyelitis (EAE) [23],
experimental collagen-induced arthritis (CIA) and asthma [24].
As a mirror image of these findings, GITR-deficient mice
(GITR
2/2) show significantly reduced inflammatory reactions as
compared to wild-type animals in response to various stimuli i.e.
chronic lung injury induced by bleomycin instillation, type II
collagen-induced arthritis, TNBS (2,4,6-trinitrobenzene sulphonic
acid)-induced colitis [25–27]. In toto, these data strongly suggest
that, if properly manipulated, the GITR/GITRL pathway could
represent an interesting therapeutic target in quite distinct settings.
As mentioned, GITR triggering is beneficial in the infectious and
tumor setting. Conversely, in the particular case of autoimmunity,
while GITR activation appears counterproductive, no reagents
were available until recently to assess whether effective blockade of
the GITR/GITRL interaction could inhibit lymphocyte auto-
reactivity and prevent autoimmunity.
In this study, we have examined, for the first time, the role of the
GITR/GITRL pathway in the course of a spontaneous autoim-
mune disease, insulin-dependent type 1 diabetes, using the non-
obese diabetic (NOD) mouse that in many aspects recapitulates the
human disease [28]. Our data demonstrate, in keeping with
previous reports in other autoimmune conditions, that GITR
triggering exacerbates autoimmune diabetes. However, our results
extend previous findings in showing that this accelerating effect is a
consequence of selective activation/costimulation of pathogenic T
cells while Tregs are spared. A second important and novel finding
is that a blocking antibody to GITRL can effectively prevent the
onset of diabetes.
Materials and Methods
Mice
NOD (K
d, I-A
g7,D
b), BDC2.5 NOD, CD28
2/2 NOD (kindly
provided by J. Bluestone, Diabetes Center and Department of
Medicine, University of California, San Francisco) and NOD-
SCID mice were bred in our animal facilities under specific
pathogen-free conditions. Colorimetric strips were used to monitor
glycosuria (Glukotest, Boehringer-Mannheim, Mannheim, Ger-
many) and fasting glycemia (Haemoglukotest and Reflolux F;
Boehringer-Mannheim).
Ethical statement: All experiments have been conducted in
accordance with European Union Council Directives (86/609/
EEC) and with institutional guidelines (INSERM: Institut National
de la Sante ´ et de la Recherche Me ´dicale). The animal facility has
an agreement delivered by the Prefecture de Police of Paris, France.
Antibody Treatment
Ten day-old NOD or CD28
2/2 NOD mice were treated with
anti-GITR antibody (rat IgG2a antibody 2F8) (Tolerx Inc.,
Cambridge, MA) or purified mouse IgGs (Jackson laboratories,
West Grove, PA). The dose used was 0.2, 0.4 or 0.8 mg/injection
i.p. on d10, d17 and d24 of life. Anti-GITRLigand antibody (rat
IgG1 antibody YGL 386.2 [5]) was administered i.p. at the dose of
1 mg/injection. Eleven week-old NOD mice received 1 mg/week
for 4 weeks. In another experiment, anti-GITRL treatment was
started at 6 weeks of age in CD28
2/2 NOD mice (week 6 to 9
included).
Histology
Stomach, pancreas, salivary glands and thyroid were fixed in
4% formalin and processed according to standard methods. Five
mm thick paraffin sections stained with hematoxylin-eosin-safran
were examined.
Adoptive Transfer
Total splenocytes were recovered from 32-week-old diabetes-
free NOD mice that have been treated with anti-GITRL antibody
(from week 11 to 14 of life). After depletion of B cells by magnetic
bead cell sorting (Miltenyi Biotech), Tregs were removed on the
basis of their expression of CD25 or CD62L. Purity of the sorted
cells was 90–95%. CD25
2CD62L
2 T cells were then injected i.v.
into 6-week-old NOD-SCID mice (10
6/recipient) and diabetes
was monitored 2 times a week until disease occurred.
Infusion of CFSE-Labeled BDC2.5 Cells
CD4
+ T cells were purified from BDC2.5 NOD splenocytes
[29] by magnetic cell sorting (Miltenyi Biotech, Germany).
BDC2.5 T cells represent more than 80% of the CD4
+ population
[30]. The cells were labeled with carboxyfluorescein diacetate
succinimidyl ester (CFSE, 1 mM, 10 min at 37uC) and transferred
i.v. into 3 to 4-wk-old NOD mice (10
7/recipient). Recipient
animals were treated either with anti-GITR (1 mg/injection) or
with anti-GITRLigand antibodies (1 mg/injection) on day 0, 1
and 4 after BDC2.5 T cell infusion. Pancreas, spleen, pancreatic
and mesenteric lymph nodes were harvested on day 7. Pancreatic
islets were isolated by Histopaque gradient (Sigma, France) after
collagenase P digestion (0.6 mg/ml, 15 min at 37uC) and
infiltrating T cells were subsequently collected after islet trypsin/
EDTA treatment.
Flow Cytometry
CD25, CD4, CD8, CD44 and CD69 antibodies were obtained
from PharMingen-BD (San Diego, CA). The biotinylated anti-
GITR antibody (clone YGITR 765.4, rat IgG2b) previously
described [5,31] was used. Foxp3 intracellular staining was
performed according to the manufacturer’s instructions
(eBioscience, San Diego, CA). The class II MHC tetramer
carrying a BDC2.5 T cell-specific mimotope (tetAg7/p79) was
GITR/GITRL Pathway in Diabetes
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PE-labeled tetramers (5 mg/ml) at 37uC for 3 hrs. Cell surface
antibodies were added during the last 30 min of incubation.
In Vitro Proliferation Assays
CD4
+CD25
+ and CD4
+CD25
2 Tc e l l s( 2 610
4 cells/well) were
cultured at a 1:1 ratio and stimulated with CD3 antibody (2.5 mg/ml)
and APCs. To assess GITR costimulatory function, CD4
+CD25
+ or
CD4
+CD25
2 T cells were stimulated with CD3 antibody (145 2C11,
0.5 mg/ml) and increasing concentrations of anti-GITR antibody. In
other experiments, CD4
+CD25
+ T cells were first stimulated with
CD3 antibody alone (0.5 mg/ml) or in combination with anti-GITR
antibody (50 mg/ml) for 48 hrs and were then co-cultured with
freshly isolated CD4
+CD25
2 T cells in the presence of APCs and
CD3 antibody. In all settings, cells were incubated for 72 hrs and
pulsed with [
3H]-thymidine (Amersham). Data from the co-cultures
were expressed as the % inhibition=[12(cpm (CD4
+CD25
2 plus
CD4
+CD25
+)/cpm CD4
+CD25
2)]6100.
Elispot Assay
PVDF plates (Millipore, St Quentin-en-Yvelines, France) were
coated overnight with anti-IFN-c antibody (U-Cytech, Utrecht,
the Netherlands). CD4
+CD25
2 or CD8
+ T cells were added
(1.5610
5/well) and stimulated with CD3 antibody (0.05 mg/ml)
and increasing concentrations of anti-GITR antibody for 20 hr. In
additional experiments, CD4
+BDC2.5 T cells were cultured with
an agonist mimotope peptide (1040-51, 2 ng/ml). After cell
removal, IFN-c secretion was detected with biotinylated anti-
IFN-c antibody, streptavidin-horseradish peroxidase and 3-amino-
9-ethylcarazole (AEC). All IFN-c spot readouts were expressed as
spot-forming cells (SFC)/10
6 cells.
Statistical Analysis
The occurrence of diabetes was plotted using the Kaplan-Meier
method. The statistical comparison between the curves was
performed using the logrank (Mantel-Cox) test. In addition, results
were analyzed using the Student’s t test when appropriate.
Results
1) GITR Triggering Boosts Diabetogenic T Cells in NOD
Mice both In Vivo and In Vitro
As already mentioned, in various models of autoimmunity
(autoimmune gastritis, EAE, CIA), disease exacerbation has been
reported following administration of an agonistic anti-GITR
antibody, DTA-1, produced by the group of S. Sakaguchi [1].
Here, using another agonistic antibody, we studied the effect of
GITR triggering in autoimmune insulin-dependent diabetes. To
that aim, we used two different models, namely conventional
NOD mice and BDC2.5 NOD mice that express a transgenic
TCR derived from a pathogenic (‘diabetogenic’) CD4
+ T cell
clone [29].
a) Acceleration of insulitis and diabetes progression. Ten
day-old female NOD mice were injected i.p. with increasing doses
of a GITR-specific antibody, 2F8, (0.2, 0.4 or 0.8 mg/injection on
day 10, 17 and 24 of life). The anti-GITR antibody used in our
study, like the DTA-1 produced by the group of Sakaguchi [1], is
agonistic. Control mice were treated with purified mouse IgGs. As
shown in figure 1A, anti-GITR-treated mice showed a significant
and quite impressive acceleration of overt diabetes onset; mice
receiving the higher anti-GITR dose developed hyperglycemia and
glycosuriaby 6–8 weeks of agethat is 5–7weeks beforediseaseonset
in control NOD females. The effect was dose-dependent; at 12
weeks of age, diabetes was observed in 80%, 50% and 35%of NOD
females treated with 0.8 mg, 0.4 mg or 0.2 mg of anti-GITR,
respectively (figure 1A). Consistent with this marked acceleration of
disease,histological examination ofpancreatashoweda significantly
more rapid progression from benign to aggressive/destructive
insulitis in anti-GITR-treated NOD mice as compared to controls
(figure 1B). Thus,by 8 weeks of age, 82% ofthe islets were massively
infiltrated as compared to 25% in control animals (figure 1B).
Anti-GITR-treated NOD mice were also examined for the
occurrence of other autoimmune manifestations including sialitis,
gastritis and thyroiditis (figure 1C). As compared to control mice,
anti-GITR-treated NOD females exhibited more severe and
rapidly progressing sialitis. Gastritis was also observed in 12% of
the treated animals but remained modest. Finally, histological
analysis did not reveal any sign of autoimmune thyroiditis (data
not shown).
Major lymphocyte subsets were analyzed in the spleen of anti-
GITR-treated and control animals. At 4 weeks of age (i.e. 2–3 days
after the last injection), anti-GITR-treated mice exhibited
significantly higher proportions of both CD4
+ and CD8
+ T cells
as compared to IgG-treated controls (33.7% versus 13.4% for
CD4 and 12.2% versus 5.8% for CD8) (figure 2A). The pattern
was back to normal by 2 weeks after the end of treatment
(figure 2A).
At early time points after anti-GITR treatment, clear pheno-
typic evidence of T cell activation was observed within the CD4
+
compartment as assessed by an increase in CD69 and CD44
expressing cells and a decrease in CD62L
high expressing cells (data
not shown). Moreover, in anti-GITR-treated NOD mice, very
high proportions of CD4
+CD25
+ T cells expressed CD103 (.60%
at 4 weeks of age) (figure 2B), an effect that progressively declined
after the end of the treatment (45% and 35% of CD103
+ were
observed at 9 or 12 weeks of age, respectively).
As already reported in the literature, GITR is constitutively
expressed by CD4
+CD25
+ Tregs. The proportion of
CD4
+CD25
+ T cells was not affected by anti-GITR antibody
treatment. In treated animals, GITR-expressing cells were coated
by the in vivo-injected antibody, a phenomenon which, in mice
receiving the highest dose, lasted 4–5 weeks after treatment (data
not shown).
b) GITR ligation on effector T cells is costimulatory in
vitro. To further investigate the costimulatory role of GITR on
pathogenic/effector T cells, CD4
+CD25
2 T cells from anti-
GITR-treated or control NOD mice were purified and stimulated
in vitro with increasing doses of CD3 antibody. Results showed that
CD4
+CD25
2 T cells from anti-GITR antibody-treated NOD
mice proliferated better even at the lowest dose of anti-CD3
(0.05 mg/ml: 29618 cpm as compared to 5050 cpm for controls;
p,0.0001) thus confirming the increased activation pattern
exhibited by CD4
+ T cells following GITR triggering (figure 3A).
In another set of experiments, CD4
+CD25
2 T cells from non
manipulated NOD mice cultured in presence of low concentrations
of anti-CD3 showed a dose-dependent proliferative response
following addition of increasing amounts of anti-GITR antibody
(figure 3B). Moreover, using an ELISPOT assay, we measured IFN-c
production by CD4
+CD25
2 or CD8
+ Tc e l l sa f t e ra2 0 h r
s t i m u l a t i o ni np r e s e n c eo fs u b - o p t i mal concentrations of anti-CD3
and increasing doses of anti-GITR (figure 3C). The same experiment
was performed using transgenic CD4
+BDC2.5 T cells stimulated
with an agonist mimotope peptide (1040-51) (instead of anti-CD3). In
both cases, addition of anti-GITR antibody resulted in a greater IFN-
c production in a dose-dependent fashion (figure 3C).
c) GITR triggering enhanced in vivo proliferation and
migration of effector T cells to the pancreas. The
diabetogenic CD4
+ Th1 cell clone BDC2.5, from which the
GITR/GITRL Pathway in Diabetes
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characterized beta-cell-specific autoantigen presented in the
context of NOD (H2
g7) class II MHC molecules [32–34].
Transgenic BDC2.5 cells are highly pathogenic. When the
transgene is expressed in the NOD-SCID or RAG
2/2 NOD
backgrounds, all T cells express the BDC2.5 TCR (since
recombination of endogenous TCRa chains is prevented)
resulting in a massive destructive infiltration of pancreatic islets
(insulitis) and overt diabetes two to three weeks after birth
[29,33,34]. As described by the group of D. Mathis, when
adoptively transferred into intact NOD mice, transgenic BDC2.5
T cells rapidly migrate to the pancreatic lymph nodes where they
actively proliferate before invading the islets [35]. We used this
model to better assess the effect of anti-GITR on effector T cells in
vivo. CFSE-labeled transgenic CD4
+BDC2.5 T cells were injected
i.v. into 3-week-old NOD mice and their distribution and
expansion was monitored in anti-GITR-treated and control
recipients. Anti-GITR antibody was administered on day 0, 1
and 4 following BDC2.5 cell infusion; pancreatic lymph nodes as
well as pancreatic islets were recovered on day 7. To specifically
detect CD4
+BDC2.5 T cells, we used I-A
g7 MHC class II
tetramers (tetp79) presenting a synthetic peptide 1040-79 (p79)
selectively recognized by the BDC2.5 clone [30,36]. The number
of both CD4
+ and CD8
+ T cells accumulating within the islets was
3–4 fold higher in recipients treated with anti-GITR antibody as
compared to controls (figure 4A, p,0.003). Interestingly, in the
islet infiltrate, the proportion of CD8
+ T cells increased from 18%
to 31% while, in parallel, in pancreatic lymph nodes it decreased
from 32% to 23% (figure 4B). The proportion of total CD4
+ T
cells remained unchanged in these two compartments (figure 4A
and B). However, a significantly higher proportion of BDC2.5 T
cells (stained by the Ag7/p79 tetramer) was observed in the islets,
but not in pancreatic lymph nodes, of recipients treated with anti-
GITR antibody as compared to controls (11.5% versus 1.3%,
figure 4A, p,0.04). BDC2.5 T cells actively proliferated in
pancreatic lymph nodes and in the islets of recipient mice. This
proliferation was clearly enhanced following anti-GITR treatment;
84% of islet-infiltrating BDC2.5 T cells underwent more than 5
divisions (figure 4C). Similarly, only 21% of BDC2.5 T cells
present in pancreatic lymph nodes of anti-GITR-treated animals
were non-dividing as compared to 49% in the control mice.
BDC2.5 T cells were mostly found in the close vicinity of the target
organ. A minor proportion of them were detected in the spleen
and the mesenteric lymph nodes of recipient mice; they did not
proliferate and their frequency did not increase following anti-
GITR treatment (data not shown).
Figure 1. Exacerbation of diabetes incidence in NOD mice following treatment with anti-GITR antibody. (A) Ten day-old female NOD
mice were treated with an antibody against GITR. Mice having received purified mouse IgGs were used as controls. The dose used was 0.2 mg (n=6),
0.4 mg (n=6) or 0.8 mg (n=12)/injection/mouse i.p. once a week on d10, d17 and d24 of life. Onset of diabetes was significantly accelerated in a
dose-dependent manner (for 0.8 mg/injection, p,0.003). (B) Histological analysis of pancreas from anti-GITR antibody-treated NOD mice killed at
various ages. The severity of aggressive insulitis was significantly increased at 9 and 12 weeks of age (p,0.0005 of both ages). (C) Histological analysis
of stomach and salivary glands of NOD mice treated with anti-GITR antibody.
doi:10.1371/journal.pone.0007848.g001
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+CD25
2 T cells issued from the spleen of 6-wk-old NOD mice
injected with anti-GITR antibody (0.8 mg) or PBS (controls) on d10, d14 and d24 in response to increasing concentrations of anti-CD3 antibody. (B)
CD4
+CD25
2 T cells recovered from the spleen of unmanipulated NOD mice were stimulated with coated CD3 antibody (0.5 mg/ml) in the presence of
increasing concentrations of anti-GITR antibody ranging from 0.08 to 50 mg/ml. (C) IFN-c Elispot assay. CD4
+CD25
2 or CD8
+ T cells from
unmanipulated NOD mice were stimulated (1.5610
5/well) with soluble CD3 antibody (0.05 mg/ml) and increasing concentrations of anti-GITR
antibody (0.08 to 100 mg/ml) for 20 hrs. In the right panel, CD4
+BDC2.5 T cells were used and stimulated with an agonist mimotope peptide (1040-51,
2 ng/ml) and anti-GITR antibody. IFN-c spot readouts are expressed as spot-forming cells (SFC)/10
6 cells. The results shown are representative of at
least three independent experiments.
doi:10.1371/journal.pone.0007848.g003
Figure 2. Phenotypic analysis of the splenic T cell compartment in anti-GITR antibody-treated NOD mice. (A) CD4 and CD8 staining in
total spleen cells recovered from NOD mice treated with 0.8 mg/injection of anti-GITR antibody and sacrificed at different ages. (B) CD25 staining in
CD4 gate and CD103 staining in CD4
+CD25
+ T cell gate.
doi:10.1371/journal.pone.0007848.g002
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a) No effect of in vivo and in vitro anti-GITR treatment on
Treg function. It has been suggested that ligation of GITR
inhibits the suppressive capacity of Tregs [1,4,8,37]. We
investigated the in vitro suppressive capacities of the CD4
+CD25
+
T cells isolated from the spleen of GITR antibody-treated mice
using the conventional non antigen-specific co-culture model.
CD4
+CD25
+ and CD4
+CD25
2 T cells were recovered from
NOD mice 2 weeks after the last anti-GITR injection. As shown on
figure 5A, CD4
+CD25
+ T cells from anti-GITR-treated NOD mice
efficiently suppressed the proliferation of CD4
+CD25
2 T cells
recovered from the same donor. To further examine if GITR
triggering altered the regulatory properties of the CD4
+CD25
+
subset, we performed criss-cross co-cultures. CD4
+CD25
+ T cells
from anti-GITR-treated NOD mice suppressed proliferation of
CD4
+CD25
2 T cells from control mice as efficiently as Tregs from
the same control mice (figure 5A). FoxP3 expression was
investigated and was detected in the majority of the CD4
+CD25
+
T cellsboth inanti-GITR-treatedandincontrolanimals(figure 5B).
Using another in vitro experimental design, we studied the effect
of GITR triggering on TCR-stimulated CD4
+CD25
+ T cells
recovered from non-manipulated NOD mice. We showed that
addition of increasing concentrations of the anti-GITR agonist
antibody resulted in a dose-dependent enhancement of
CD4
+CD25
+ T cell proliferation (figure 5C) i.e. CD4
+CD25
+ T
cells lost their anergic state in response to CD3 antibody.
However, these CD4
+CD25
+ T cells that have been previously
stimulated with a combination of CD3 and GITR antibodies
exhibited suppressive capacities similar to the one afforded by
freshly isolated CD4
+CD25
+ T cells or CD4
+CD25
+ T cells
cultured with CD3 antibody alone (figure 5D).
b) The CD28
2/2 NOD mouse model. To further confirm
that anti-GITR treatment selectively acted on effector T cells but
spared Tregs, we used NOD mice deficient in the cd28 encoding
gene (CD28
2/2 NOD). These mice are deprived of natural
CD25
+FoxP3
+ natural Tregs and they exhibit exacerbated Th1
responses and accelerated diabetes [38,39]. Anti-GITR antibody
treatment was performed in 10 day-old female CD28
2/2 NOD
mice (0.8 mg/injection on d10, d17 and d24 of life). As expected,
66.7% of control animals that received control IgGs showed overt
disease by 15 weeks of age (figure 6A). Anti-GITR-treated mice
showed acceleration of disease onset reaching 100% of diabetes
Figure 4. In vivo GITR costimulatory action on BDC2.5 T cells. Three to four-week-old NOD mice were infused with 10
7 CFSE-labeled
CD4
+BDC2.5 T cells and were treated or not with anti-GITR antibody on day 0, 1 and day 4 after transfer. Recipient mice were sacrified on day 7 and
cell suspensions were recovered from the pancreatic islets and lymph nodes and analyzed by flow cytometry. (A) FACS analysis in the pancreatic
islets. Upper panel: proportion of CD4
+ and CD8
+ T cells detected within the islets; lower panel: tet/p79 tetramer staining (MHC class II tetramer
carrying a BDC2.5 T cell-specific peptide p79) in the CD4
+ T cell gate (p,0.04). Histogram: islet infiltrating CD4
+ and CD8
+ T cell count (*p,0.003). (B)
FACS analysis in the pancreatic lymph nodes (PLN). Upper panel: distribution of CD4
+ and CD8
+ T cells, lower panel: tet/p79 tetramer staining in the
CD4
+ T cell gate. (C) Proliferation of BDC2.5 T cells in the pancreatic lymph nodes (PLN) and islets of recipient NOD mice measured by CFSE staining in
the CD4
+Tet/p79
+ T cell gate. The results shown here are representative of three independent experiments.
doi:10.1371/journal.pone.0007848.g004
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recovered from 9-week-old anti-GITR antibody-treated CD28
2/2
NOD mice showed more than 95% of massively infiltrated and
destroyed islets (as compared to 43% in the control group)
(figure 6B).
3) Blockade of GITR Ligand Is Effective at Preventing
Disease Progression
a) Treatment of NOD mice with a short anti-GITRL
course protects from diabetes. As a whole, the data
presented above clearly suggest that GITR triggering promotes
exacerbation of autoimmune diabetes consequent to the activation
of diabetogenic T cells without significantly affecting the Treg
pool. We therefore hypothesized that blocking GITR/GITRL
interaction may represent a promising therapeutic strategy to
control diabetes development.
To directly test this hypothesis, a monoclonal anti-GITRL
antibody (clone YGL 386.2), that interferes with the GITR/
GITRL interaction, was injected intraperitonealy (1 mg/injec-
tion/week) at a late pre-diabetic stage (11-week-old) for only 4
consecutive weeks. Diabetes incidence was significantly reduced:
0% versus 78% diabetes in the control group at 20 weeks of age,
16.6% versus 100% at 25 weeks of age and 33% versus 100%
diabetes at 30 weeks of age (figure 7A). Phenotypic analysis of
various lymphoid organs (spleen, mesenteric, pancreatic lymph
nodes) did not reveal any major modification of the T cell
compartment as compared to untreated NOD mice (data not
shown). In particular, the proportion and the suppressive functions
of CD4
+CD25
+FoxP3
+ regulatory T cells recovered from anti-
GITRL antibody-treated NOD mice at different time points
following treatment were not modified as compared to age-
matched controls (data not shown).
b) Anti-GITRL antibody-protected NOD mice harbor
pathogenic T cells. We next tested whether protected NOD
mice still harbored pathogenic T cells. Total splenocytes were
harvested from 32-week-old anti-GITRL antibody-treated
diabetes-free NOD mice and were depleted of regulatory T cells
i.e. CD4
+CD25
+ T cells and CD4
+CD62L
+ T cells [39–41]. The
CD25
2CD62L
2 T cell fraction, that included diabetogenic
effectors [42], was adoptively transferred into 6-week-old NOD-
SCID mice (10
6/recipient). As shown on figure 7B,
CD25
2CD62L
2 T cells from anti-GITRL-treated donors were
still able to transfer disease as efficiently as T cells from overtly
diabetic NOD mice. This result argues against the deletion
Figure 5. GITR triggering does not abrogate regulatory T cell function. (A) In vitro suppressive capacities of CD4
+CD25
+ T cells recovered
from anti-GITR antibody-treated NOD mice. CD4
+CD25
2 and CD4
+CD25
+ T cells were recovered from the spleen cell of 6-week-old NOD mice injected
with anti-GITR antibody (0.8 mg on day 10, 17 and 24) or of control mice. Criss-cross co-cultures were performed by incubating the CD4
+CD25
+ T cells
from anti-GITR-treated NOD mice with CD4
+CD25
2 T cells from control animals and inversely. The two T cell subsets (CD25
+ and CD25
2) were
cultured at a 1/1 ratio in presence of APCs and CD3 antibody for 72 hrs. Data represent the mean of 4 experiments. (B) FoxP3 expression by
CD4
+CD25
+ T cells recovered from the spleen of 5-week-old NOD mice treated with anti-GITR antibody. (C) CD4
+CD25
+ T cells from unmanipulated
NOD mouse spleen were stimulated with coated CD3 antibody (0.5 mg/ml) in the presence of increasing concentrations of anti-GITR antibody ranging
from 0.08 to 50 mg/ml. (D) CD4
+CD25
+ T cells were recovered from 6-week-old NOD mice and cultured with CD3 antibody (0.5 mg/ml) or CD3+GITR
antibodies (50 mg/ml) for 48 hrs. Cells were harvested, washed and their suppressive capacity was evaluated after 72 hrs incubation with freshly
isolated CD4
+CD25
2 T cells. Freshly isolated CD4
+CD25
+ T cells were used as controls. The results shown here are representative of at least three
experiments.
doi:10.1371/journal.pone.0007848.g005
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treatment.
4) Blockade of the GITR/GITRL Pathway Reduced In Vivo
Proliferation and Migration of Effector T Cells to the
Pancreas
The data presented above indirectly suggest a critical role for the
GITR/GITRL interaction in the migration of pathogenic effector
T cells to the target tissue. To assess more directly whether blockade
of the GITR/GITRL pathway directly interfered with the
activation and/or migration of effector T cell reactivity, we took
advantage of the experimental design described above using CFSE-
labeled CD4
+BDC2.5 T cells. BDC2.5 T cells were infused into 4-
week-old NOD mice that were then treated with 1 mg anti-GITRL
antibody on day 0, 1 and day 4. Spleen, mesenteric and pancreatic
lymph nodes as well as pancreatic islets were recovered on day 7.
The analysis of immune cells infiltrating the pancreatic islets
showed that less CD4
+ T cells were detected after injection of anti-
GITRL antibody (17.9% versus 24.8% in islets from untreated
animals) (figure 8A, p,0.05). Among these CD4
+ T cells, 13.1%
were stained with tetp79 as compared to 18.2% in controls
(figure 8B, p,0.04). In other words, proliferating BDC2.5 T cells
represent 2.3% of the total lymphocytes found within the
pancreatic islets of anti-GITRL-treated recipient mice as com-
pared to 4.5% in untreated animals (data not shown). Interest-
ingly, the proportion of CD8
+ T cells present within the islets was
decreased after anti-GITRL antibody treatment as compared to
untreated recipient NOD mice (figure 8A, p,0.02).
BDC2.5 T cells accumulated less (3.3% of total CD4
+ Tc e l l s
versus 5.1% in untreated animals, figure 8B, p,0.05) and,
importantly, proliferated less in pancreatic lymph nodes of NOD
mice treated with anti-GITRL antibody (Figure 8C). Only 22% of
the BDC2.5 T cells underwent at least one division after
administration of anti-GITRL antibody as compared to 34.5%
without treatment (figure 8C). Phenotypic analysis was performed on
the BDC2.5 T cells infused into NOD mice treated or not with anti-
GITRL antibody. Expression of CD44
high was clearly detected on T
cells that proliferated in the pancreatic lymph nodes of recipient mice
(figure 9A). However, correlating with the previous results (figure 8),
less BDC2.5 T cells were CFSE
lowCD44
high after administration of
anti-GITRL antibody (figure 9A, p,0.05). Similarly, BDC2.5 T cells
that migrated to the pancreatic lymph nodes of anti-GITRL
antibody-treated mice expressed lower levels of CD69 (figure 9B).
Interestingly, we observed that CD69 staining intensity decreased as
Figure 6. Acceleration of diabetes incidence in CD28
2/2 NOD
mice following administration of anti-GITR antibody. (A) Ten
day-old female CD28
2/2 NOD mice (n=8) were treated with anti-GITR
antibody or purified Igs. The dose used was 0.8 mg/injection/mouse i.p.
once a week on d10, d17 and d24 of life. Anti-GITR antibody treatment
significantly exacerbated diabetes onset in all animals used (p,0.007).
(B) Histological analysis of pancreas recovered from 9-week-old female
CD28
2/2 NOD mice injected with anti-GITR antibody or control Igs.
Invasive insulitis was clearly worsened in anti-GITR-treated animals
(p,0.011).
doi:10.1371/journal.pone.0007848.g006
Figure 7. In vivo administration of anti-GITRLigand antibody
protects from diabetes development. (A) Treatment with anti-
GITRL antibody started at 11 weeks of age in pre-diabetic NOD mice,
1 mg antibody/week i.p. on week 11 to 14 (n=8). Significant protection
was observed as compared to control animals (33.3% diabetes versus
100% in the control group at 32 weeks of age, p,0.001). (B) Adoptive
transfer into NOD-SCID recipients of CD25
2CD62L
2 T cells recovered
either from the spleen of 32-week-old diabetes-free anti-GITRL
antibody-treated NOD mice (10
6/mouse) or from the spleen of overtly
diabetic animals. Both populations were able to transfer diabetes with a
similar efficiency.
doi:10.1371/journal.pone.0007848.g007
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underwent several rounds of cell division did not express CD69
(figure 9B). This CFSE
lowCD69
2 population is present at a lower
proportion in anti-GITRL antibody-treated mice (p,0.04). CD69 is
an early activation marker. The lack of expression of CD69 on a
fraction of proliferating CFSE
low T cells, as well as their high
expression of CD44, suggest that, in untreated NOD mice, BDC2.5
T cells have already gone through several rounds of activation and
exhibit an effector/memory-like phenotype. This is not the case in
anti-GITRL antibody-treated mice.
Some BDC2.5 T cells did proliferate and acquired the activation
markers CD44
high and CD69 in the mesenteric lymph nodes of anti-
GITRL antibody-treated mice (figure 9A and B). In contrast,
BDC2.5 T cells detected in the spleen of recipient NOD mice
(around 3% of total T cells) did not proliferate nor express CD44
high
or CD69, independently of any antibody treatment (data not shown).
5) The Protective Effect of Anti-GITRL Is Independent of
the Presence of Treg
To further investigate the effect of blocking GITR/GITRL
pathway on effector T cell functions, pre-diabetic 6-week-old
CD28
2/2 NOD mice were treated with an anti-GITRL antibody
(1 mg/injection on week 6 to 9). Administration of this anti-
GITRL antibody significantly delayed (but did not abrogate)
diabetes development in CD28
2/2 NOD mice (figure 10), as
opposed to what observed with the agonist anti-GITR antibody
(figure 6A).
Discussion
Type 1 diabetes is a prototypic organ-specific autoimmune
disease resulting from the selective destruction of insulin-secreting
beta-cells within pancreatic islets of Langerhans by an immune-
mediated inflammation involving autoreactive CD4
+ and CD8
+ T
lymphocytes and monocytic cells which infiltrate pancreatic islets
(insulitis) [43]. Current treatment is substitutive i.e. chronic use of
exogenous insulin which is, in spite of significant advances, still
associated with major constraints (multiple daily injections, risks of
hypoglycemia) and a lack of effectiveness over the long term in
preventing severe degenerative complications. Finding a cure for
autoimmune diabetes is a real health challenge since its incidence
steadily increases in industrialized countries [44,45]. Our present
results demonstrate a key role of the GITR/GITRL pathway in
Figure 8. Blockade of GITR/GITRLigand pathway decreased BDC2.5 T cell migration and proliferation in the pancreatic lymph
nodes. Three to four-week-old NOD mice were infused with 10
7 CFSE-labeled CD4
+BDC2.5 T cells and were treated or not with anti-GITRL antibody
on day 0, 1 and day 4 after transfer. Recipient mice were sacrified on day 7 and cell suspensions were harvested from mesenteric and pancreatic
lymph nodes and from pancreatic islets. (A) Staining of islet-infiltrating CD4
+ and CD8
+ T cells in recipient NOD mice. Less T cells were detected after
anti-GITRL treatment (p,0.05 for CD4
+ T cells, p,0.02 for CD8
+ T cells). (B) Detection of BDC2.5 T cells using the Tet/p79 tetramer in various organs
after gating on CD4
+ T cells. Reduced numbers of BDC2.5 T cells were found in pancreatic lymph nodes and islets of anti-GITR-treated recipients
(p,0.05 and p,0.04, respectively). (C) Proliferation of the infused BDC2.5 T cells followed by the CFSE staining in the CD4
+Tet/p79
+ T cell gate.
BDC2.5 T cells were present in reduced number and proliferated less the pancreatic lymph nodes of anti-GITRL antibody-treated NOD mice. The
results shown here are representative of three independent experiments.
doi:10.1371/journal.pone.0007848.g008
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as a therapeutic target. On one hand, GITR triggering following in
vivo administration of an agonistic anti-GITR monoclonal
antibody promotes a clear-cut exacerbation of disease. On the
other hand, adequate pharmacological blockade of this pathway
following short-term in vivo treatment with an anti-GITRL
antibody is effective at protecting from disease development. For
the sake of clarity, we shall discuss these two aspects of our work
consecutively.
The capacity to significantly up-regulate immune responses
upon GITR triggering is quite remarkable and covers the whole
spectrum of antigens that have been studied, including infectious
and tumor antigens, autoantigens and alloantigens. This effect was
initially described by the group of S. Sakaguchi in autoimmunity
with the DTA-1 antibody (a rat anti-mouse GITR monoclonal)
they had produced using natural CD4
+CD25
+ Tregs as an
immunogen [1]. The DTA-1 antibody blocked the in vitro
suppressive ability of CD4
+CD25
+ T cells. Additional experiments
confirmed the agonistic properties of DTA-1 through active GITR
signaling and not mere blockade of the receptor; only the intact
antibody but not Fab fragments mediated the effect [1]. In vivo,
only 3 injections of the anti-GITR antibody (once a week for 3
weeks) to very young BALB/c mice (2 week-old) induced by 3
months of age histological and serological evidence of autoimmune
gastritis [1], a situation partly resembling that induced following
elimination of CD4
+CD25
+ T cells by day 3 thymectomy in
BALB/c mice [46]. In EAE, the same anti-GITR antibody
significantly increased disease severity and CNS inflammation and
induced elevated levels of antigen-specific T cell proliferation and
cytokine production [23]. Similarly, both Th1- and Th2-mediated
inflammatory disorders (collagen-induced arthritis and asthma,
respectively) were exacerbated after injection of anti-GITR [24].
In the present report, we extended these data to a spontaneous
autoimmune insulin-dependent diabetes model, the NOD mouse,
that recapitulates many aspects of the human disease. Using
another agonistic anti-GITR antibody, 2F8, we found a very
significant acceleration of disease onset following a short treatment
course (3 injections, once a week) started in young mice (10 days of
age). As in the case of DTA-1, our 2F8 antibody did not eliminate
GITR-expressing cells. Histological autoimmune sialitis, that is
spontaneously observed in NOD mice, was also worsened in anti-
GITR-treated animals. However, in contrast to what was observed
in the BALB/c mouse strain [1], severe gastritis was not induced in
NOD mice. In the autoimmune or inflammatory models cited
above, the authors could not conclude whether the disease
accelerating effect of GITR triggering was due to a decrease in the
functional capacity of Tregs or to a stimulating/costimulatory
effect on pathogenic T cells that also express GITR. We addressed
Figure 9. Blockade of GITR/GITRLigand pathway decreased BDC2.5 T cell activation in the pancreatic lymph nodes. CD44 (panel A)
and CD69 (panel B) staining were performed on CFSE-labeled BDC2.5 T cells that were previously infused into 3 to 4-week-old NOD mice. Recipient
mice were treated or not with anti-GITRL antibody on day 0, 1 and 4 after cell infusion. Mesenteric and pancreatic lymph nodes were recovered on
day 7. The proportion of dividing cells (CFSE
low) expressing CD44
high and CD69 decreased in the pancreatic lymph nodes of anti-GITRL antibody-
treated NOD mice (p,0.05 and p,0.04, respectively). BDC2.5 T cells that migrated to mesenteric lymph nodes showed increased proliferation as well
as CD44
high and CD69 expression.
doi:10.1371/journal.pone.0007848.g009
Figure 10. Anti-GITRLigand antibody treatment delays diabe-
tes in CD28
2/2 NOD mice. (A) Anti-GITRL antibody was administered
into pre-diabetic 6-week-old CD28
2/2 NOD mice, 1 mg/injection/week
for 4 consecutive weeks (n=8). Diabetes development was significantly
delayed as compared to the control group (p,0.023).
doi:10.1371/journal.pone.0007848.g010
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higher proportions of CD4
+ and CD8
+ T cells showing an
activated phenotype in anti-GITR-treated mice as compared to
controls pointing, though indirectly, to an accelerated maturation/
differentiation of peripheral T cells. Moreover, we collected
evidence arguing for a major costimulatory effect on pathogenic/
diabetogenic T cells of anti-GITR antibody contrasting with a lack
of effect on Tregs.
First, in vitro, increasing concentrations of anti-GITR antibody
exerted a costimulatory effect on the proliferative capacity and/or
the IFN-c production of CD4
+CD25
2 T cells (depleted of Tregs)
and CD8
+ T cells in response to a polyclonal stimulation (i.e. anti-
CD3). The same effect was observed in the context of an
autoantigen-specific stimulation using CD4
+ T cells from BDC2.5
NOD mice (that express an islet autoantigen-specific transgenic T
cell receptor): a dose-dependent costimulatory effect was observed
upon addition of anti-GITR as assessed by the IFN-c production.
Similarly, CD4
+CD25
2 T cells recovered ex vivo from anti-GITR-
treated mice exhibited a significantly enhanced proliferative
capacity to suboptimal doses of anti-CD3. These findings fit with
observations reported in models of EAE, asthma and collagen-
induced arthritis showing enhanced CD4
+ T cell activation,
proliferation and cytokine production after administration of
agonist anti-GITR antibodies [23,24].
Secondly, using an in vivo model in which CFSE-labeled
pathogenic BDC2.5 NOD CD4
+ T cells were transferred into
young syngeneic recipients, we showed that, in anti-GITR-treated
recipients, the migration of pathogenic effectors to the target tissue
and its draining lymph nodes (i.e. within the infiltrated islets and
pancreatic lymph nodes) as well as their in situ proliferation was
greatly enhanced as compared to untreated control recipients.
This phenomenon was accompanied by an enhanced CD8
+ T cell
migration within the islets of treated animals that may result from
the combined effect of GITR triggering and the activating/
chemoattracting factors produced by activated CD4
+BDC2.5 T
cells.
Third, no effect of anti-GITR antibody on Treg function was
found as assessed by a completely normal ability to suppress, in the
conventional coculture system, of Tregs pre-treated in vitro with
anti-GITR or recovered ex vivo from anti-GITR-treated NOD
mice. These results confirm and extend previous results by
McHugh et al. showing that GITR triggering on Tregs during a
pre-activation phase (with anti-CD3 and IL-2) did not abrogate
their suppressive capacity in a subsequent coculture assay with
anti-CD3 or peptide-specific stimulated CD4
+CD25
2 T cells [4].
In addition, in vivo, we were not able to detect in any lymphoid
organ a significant increase in the number or proportion of Tregs
at any time-point after administration of anti-GITR antibody
although in vitro addition of anti-GITR increased Treg prolifer-
ation in response to CD3-specific antibody stimulation.
This lack of effect on regulatory CD4
+CD25
+ T cells was
reinforced by the fact that the disease accelerating effect of anti-
GITR treatment could be obtained in the absence of thymus-
derived natural Tregs that is the case of NOD mice deficient for
CD28 (CD28
2/2 NOD). These findings contrast with initial in
vitro reports suggesting that ligation of GITR blocked the
suppressive ability of freshly isolated Tregs [1,4]. This apparent
contradiction may be reinterpreted in the light of more recent
results by Stephens et al., using GITR
2/2 mice, demonstrating
that it is the engagement of GITR on effector T cells (but not on
Tregs) which provides a co-activating signal rendering these cells
resistant to regulation and as a consequence abrogating suppres-
sion [6]. Thus, in the autoimmune setting, GITR may influence
the sensitivity of autoreactive T cells to stimulation by the cognate
autoantigens, leading to an increased autoreactivity not properly
controlled by Tregs. This possibility is further supported by data
showing that GITR signaling lowers the threshold of T cell
activation [47]. As a whole, our data suggest that the activation,
proliferation and migration of effector T cells to the target tissue
constitute the primary costimulatory effect of GITR triggering in
vivo, overcoming the potential impact of anti-GITR on Tregs.
Now, coming to blockade of GITR signaling, the salient result is
that it effectively protects from disease development. The original
and interesting finding here is that significant protection was
achieved even when anti-GITRL antibody treatment started at 11
weeks of age i.e. a late pre-diabetic stage characterized by an
already severe islet inflammation. Experiments are ongoing using
higher cumulated dosages of anti-GITRL antibody to improve the
effect (i.e. complete protection from diabetes development). In
addition, work is also in progress to test if GITRL antibody
therapy may also be effective at reversing recent onset established
diabetes in NOD mice.
Interestingly, anti-GITRL antibody treatment applied to the
two in vivo models used to study effector T cells (i.e. CD28
2/2
NOD mice and adoptive transfer of CFSE-labeled BDC2.5 T
cells) gave opposite results as compared to anti-GITR agonist
antibody treatment. Diabetes was significantly delayed yet not
abolished in anti-GITRL antibody-treated CD28
2/2 NOD mice
and BDC2.5 T cells showed reduced migration and proliferation
in the islets and pancreatic lymph nodes of anti-GITRL-treated
recipient NOD mice as compared to untreated animals. As a
mirror image with what found in the islets of anti-GITR-treated
recipients, this reduced migration of CD4
+ diabetogenic cells in
anti-GITRL antibody-treated mice correlated with a quite
dramatic reduction in the proportion of infiltrating CD8
+ T cells.
Altogether, these results highlight that changes in antigen-specific
CD4
+ T cell migration and proliferation appear to significantly
impact the recruitment of CD8
+ effectors to the target tissue.
Two possibilities can explain that, although delayed, diabetes
still occurred in anti-GITRL antibody-treated CD28
2/2 NOD
mice. First, due to the absence of naturally occurring CD4
+CD25
+
Tregs, these mice exhibited accelerated disease development
compared to wild-type NOD mice (overt diabetes is usually
observed by 8 weeks of age). Administration of anti-GITRL
antibody was performed at 6 weeks of age once too many islets
were already aggressively infiltrated to achieve significant arrest of
the process. Secondly, one cannot at this point formally exclude a
role for CD4
+CD25
+ Tregs in the protective effect of anti-GITRL
antibody. It is true that we did not observe any major modification
in terms of number/proportions or suppressive functions in the
various lymphoid organs (spleen, mesenteric and pancreatic lymph
nodes) recovered from protected wild-type NOD mice. However,
these Tregs may be important for controlling pathogenic T cells
that did not migrate into pancreatic islets and are still present at
the periphery as shown by the efficient transfer of diabetes into
NOD-SCID recipients by splenic T cells from diabetes-free anti-
GITRL-treated NOD mice.
As a whole, these results suggest that disease protection obtained
following blockade of the GITR/GITRL pathway may rely on
two distinct but not mutually exclusive mechanisms that are first, a
limitation of the activation and migration of effector cells to the
target tissue and, second, the maintenance of peripheral self-
tolerance via CD4
+CD25
+ T cell-mediated regulation.
It will be important to study the GITRL expression and its
regulation on APCs during disease progression in NOD mice. In
keeping with data reported by Kamimura et al. in a model of
contact hypersensitivity [48], one may hypothesize that APCs
expressing GITRL (that may increase in the pro-inflammatory
GITR/GITRL Pathway in Diabetes
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enhance the homing potential of GITR-expressing autoreactive T
cells.
From a more practical, clinically oriented perspective, these
results point to the use of anti-GITRL as a novel avenue for the
treatment of autoimmune type 1 diabetes. The incidence of
autoimmune diabetes has tremendously increased in industrialized
countries over the last three decades [49] and predictions for
future years are alarming [44,45]. According to two recent reports,
disease incidence has accelerated since 2000 and if present trends
continue, the number of new cases diagnosed at or before 14 years
of age will double in the next 15 years with onset at younger age
(0–4 years) [44,45]. Therefore, establishing safe immune inter-
vention strategies, that may provide a real cure for the disease, is
both an urgent need and a real medical health challenge. Given
the young age of the affected population, any candidate therapy
must be safe and avoid a sustained depression of immune
responses thus aiming at inducing or, in the case of established
diabetes, restoring immune tolerance to target autoantigens.
Major progress towards that aim has been made over the last 20
years and promising strategies are presently studied both to reverse
established disease or to prevent it based on the use of candidate
autoantigens or immune modulating drugs [50–53]. Although very
encouraging, results so far are not totally satisfactory, and, as in
many other clinical situations, one may predict that major
improvements will be achieved as dosing schedules are adjusted
and drug combinations are performed.
Our present data point to anti-GITRL antibodies as very good
potential candidates whose capacity to block the migration to the
target organ and the activation of pathogenic effectors appears
fully complementary to that of the other agents presently tested
which preferentially target T-cell mediated regulatory pathways
[51,53–59]. The question of whether an autoantigen-specific effect
may be obtained is still open. One may speculate that although
GITR is expressed on all T lymphocytes, blockade of GITR/
GITRL pathway may promote differential signaling depending on
the nature and the functional capacity of T cell targets (i.e. a naı ¨ve
T cell, an activated or a memory T cell, a Treg), thus determining
the ‘quality’ of the GITR antibody-mediated signal and the
resulting outcome.
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